Table 1.
Research progress of CAR-T cell therapy in head and neck squamous cell carcinomas (HNSCCs).
| Target | Introduction | Reference |
|---|---|---|
| Preclinical study | ||
| HER2 | CD28. CD3-ζ/CAd | [42] |
| EGFR | - | [43] |
| CD70 | 4-1BB.CD3-ζ | [44] |
| MUCI | 4-1BB.CD3-ζ/IL-12 | [45] |
| CD44v6 | CD28. CD3-ζ | [46] |
| B7-H3 | - | [47] |
| CD98 + EGFR | UniCAR-T | [48] |
| Clinical trial | ||
| ERBb2/HER2 |
NCT01818323 NCT03740256 |
[49,50] |
| EpCAM | NCT02915445 | |
| NKG2DL | NCT04107142 | |
| LMP1 | NCT02980315 | |
| Potential target | ||
| FAP | Overexpression of HNSCC cells compared to adjacent tissue controls (p < 0.0005); FAP-targeting CAR-T cells have been used in treating other solid tumors |
[44,51,52,53] |
| HER3 | Overexpression of HPV-positive HNSCC cells compared to HPV-negative HNSCC cells (p = 0.0007); HER3-targeting CAR-T cells have been used in treating mice bearing breast tumor cells |
[54,55] |
| NKGD2 | Overexpression of MICA and MICB in HNSCC cells compared to adjacent tissue controls (p < 0.0005); NKGD2-targeting CAR-T cells for treatment of acute myeloid leukemia and multiple myeloma have been used in clinical trial |
[44,56] |